Saskatchewan increases access to important diabetes medications

    REGINA, Aug. 20 /CNW/ - The Canadian Diabetes Association applauds the
Government of Saskatchewan for increasing access to insulin detemir for
residents of Saskatchewan living with diabetes. Insulin detemir, also known as
Levemir, has been added to the Saskatchewan Drug Formulary, under Exception
Drug Status (EDS) effective July 1, 2009. As well, the updated formulary now
includes NovoRapid-NOO, Apidra-AVT and Humalog-LIL within its Revised
Exception Drug Status Criteria.
    "The addition of insulin detemir to Saskatchewan's drug formulary, and
the criteria updates to insulin aspart, insulin glulisine and insulin lispro
are important steps in providing options for people living with diabetes for
whom other insulin treatments have not been effective in controlling blood
glucose levels," said James Gibbins, Executive Director, Prairies Area,
Canadian Diabetes Association. "We applaud the Government of Saskatchewan for
its commitment to improving diabetes management across the province by
increasing access to medications that will benefit people living with
    Insulin is a hormone produced by the pancreas to control the amount of
glucose (sugar) in the blood. For those living with diabetes, the pancreas
does not produce any or enough insulin, or is unable to effectively use the
insulin it does produce. As a result, glucose builds up in the bloodstream,
leading to serious health problems such as blindness, heart disease, kidney
problems, amputation, nerve damage and erectile dysfunction.
    The Saskatchewan Drug Plan and Extended Benefits program, administered by
the Saskatchewan Ministry of Health, provides coverage for a number of drug
products including nutrition products and diabetes testing agents. For more
information, visit:

    The Canadian Diabetes Association works in communities across the country
to promote the health of Canadians and eliminate diabetes through our strong
nationwide network of volunteers, employees, healthcare professionals,
researchers, partners and supporters. In the struggle against this global
epidemic, our expertise is recognized around the world. To learn more, visit or call 1-800-BANTING (226-8464).

For further information:

For further information: Allison Langridge, Associate, Marketing &
Communications, Canadian Diabetes Association, Tel: (204) 925-3800 x231,

Organization Profile

Canadian Diabetes Association

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890